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Summary We have studied the genetic alterations acquired during selection of a cloned human leukaemic
cell line (CEM/VP-1) that is 15-fold more resistant to the anticancer topoisomerase Il-inhibitor etoposide than
parental CCRF-CEM cells. CEM/VP-1 cells exhibit an 'atypical MDR' phenotype: cross resistance to other
topo II inhibitors (but not Vinca alkaloids) and expression of a drug-resistant topo II activity. Cytogenetic and
molecular studies revealed that the cell line carried multiple genetic changes affecting TOP2 genes encoding
both topo IIa and P isoforms.
CEM/VP-l was diploid, 47,XX,+ 20, and appears to have been preferentially selected from a 1% diploid
subpopulation present in the tetraploid parental cells. The same chromosomal abnormalities were present in
resistant and sensitive cells except for an acquired 3p- change most likely deleting one TOP2P allele.
PCR/DNA sequence analysis and allele-specific hybridisation showed that one of two TOP2a alleles expressed
in CEM/VP-1 cells had acquired a Lys-797+Asn codon change. This mutation lies close to the catalytic
Tyr-804 residue of the protein and may interfere with drug-induced trapping of the cleavable complex.
Alternatively, it could exert a loss of function phenotype. CEM/VP-1 cells did not exhibit codon 449 or 486
TOP2a mutations in the ATP binding domain reported in two other resistant cell lines. Diploid selection and
multiple changes observed in CEM/VP-1 cells appear to be consequences of the recessive phenotype of
at-MDR. These results may be useful in approaching the mechanisms of clinical resistance.
Resistance to multiple antitumour agents is a major problem
in cancer chemotherapy. Some tumours are resistant to
primary therapy, others become resistant during treatment.
Progress in understanding the mechanisms ofmultidrug resis-
tance (MDR) has come largely from studies of cultured cell
lines and has identified at least two distinct phenotypes,
so-called 'classical' and 'atypical' MDR (Moscow & Cowan,
1988).
Cells exhibiting 'classical' MDR are resistant to a range of
structurally unrelated lipophilic drugs including the Vinca
alkaloids, anthracyclines, actinomycin D and colchicine
(Endicott & Ling, 1989). Resistance arises from reduced in-
tracellular drug levels due to expression of the transmem-
brane P-glycoprotein efflux pump, the product of the MDR]
gene. In contrast, 'atypical MDR' (at-MDR) involves cross
resistance to drugs that inhibit the replicative enzyme, DNA
topoisomerase II (Danks et al., 1987, 1988). This ATP-
requiring dimeric protein is a structural component of
metaphase chromosomes and is responsible for chromosome
segregation via transient double strand DNA breaks (Liu,
1989). Topo II inhibiting drugs are thought to exert their
cytotoxicity by trapping a 'cleavable complex' of the enzyme
on DNA and include the epipodophyllotoxins, etoposide
(VP-16) and teniposide (VM-26), which have become promi-
nent antitumour agents effective against small cell lung car-
cinoma (SCLC), leukaemia, lymphoma and other neoplasms
(Chen et al., 1984; Nelson et al., 1984; Ross et al., 1978; Ross
et al., 1984; Tewey et al., 1984; Zwelling et al., 1981). Cells
exhibiting at-MDR do not have alterations in sensitivity to
Vinca alkaloids, P-glycoprotein levels or drug accumulation
(Beck et al., 1987; Danks et al., 1987). Instead, their salient
feature is reduced cleavable complex formation arising from
decreased topo II activity levels and/or structural changes in
the enzyme. One or both of these changes have been de-
scribed in Chinese hamster ovary cells made resistant to
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teniposide or 9-hydroxyellipticine, HL60 cells made resistant
to mAMSA and CEM cells resistant to teniposide and etopo-
side (Charcosset et al., 1988; Danks et al., 1987, 1988; Estey
et al., 1987; Glisson et al., 1986; Patel et al., 1990; Pommier
et al., 1986). Unlike the genetic dominance seen for MDRI-
mediated resistance (Endicott & Ling, 1989), cell fusion
experiments have shown that at-MDR is phenotypically
recessive to drug sensitivity (Wolverton et al., 1989).
The genetic basis underlying at-MDR is poorly under-
stood. The situation is complicated by the recent identifi-
cation in mammalian cells of two genetically distinct isoforms
of topo II, termed a (pl7O) and P (pl80) encoded by the
TOP2c and TOP2P genes recently mapped to human
chromosomes 17 and 3, respectively (Austin & Fisher, 1990;
Chung et al., 1989; Drake et al., 1989; Tan et al., 1992 and
refs therein). These proteins are differentially regulated in the
cell cycle and exhibit different sensitivities to topo II
inhibitors in vitro. Two recent studies have uncovered can-
didate resistance mutations in the TOP2a cDNA of cell lines
made resistant to amsacrine and teniposide (Bugg et al.,
1991; Hinds et al., 1991; Lee et al., 1992). The role of topo
111 in resistance has yet to be examined fully.
To investigate genetic changes involved in at-MDR, we
chose to study the acquisition of resistance to etoposide, one
of the most used topo II directed antitumour drugs. We have
developed and cloned a human leukaemic CCRF-CEM cell
line, CEM/VP-1, derived by incremental selection for resis-
tance to etoposide (Patel et al., 1990). CEM/VP-1 cells are
15-fold more resistant to etoposide than parental cells and
exhibit the hallmarks of at-MDR: cross resistance to other
topo II inhibitors including doxorubicin, teniposide and
m-AMSA but not to Vinca alkaloids; similar levels of topo II
activity compared to parental cells but much reduced
etoposide-mediated DNA cleavage by nuclear extracts; and
an etoposide-resistant topo II decatenation activity in nuclear
extracts (Patel et al., 1990). The results indicate that a struc-
tural alteration in topo II contributes to the etoposide resis-
tance of CEM/VP-1 cells.
In this paper, we use a combination of cytogenetic analy-
sis, PCR/DNA sequencing and allele-specific hybridisation to
characterise the CEM/VP-1 cell line and its TOP2 alleles. We
show that the cell line derives from a rare diploid population
in the tetraploid parental CEM cells and present evidence for
multiple genetic changes involving TOP2ac and TOP2P genes.
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Materials and methods
Cell lines and cell culture
The CCRF-CEM human leukaemic cell line kindly provided
by Dr A.P. Johnstone (Department of Cellular and
Molecular Sciences, St George's Hospital Medical School)
was grown as stationary suspension cultures in RPMI 1640
medium containing 2 mM glutamine (Gibco BRL, Paisley,
UK) and supplemented with 10% heat-inactivated foetal
bovine serum (Imperial Laboratories, Hampshire, UK),
penicillin (100 IU ml-') and streptomycin (100fig mlh'). Cells
were maintained at a density of 1.5 x 105 to 2.5 x 105 by
subculturing every 3-4 days and incubating at 37'C in an
atmosphere of 95% air and 5% CO2.
Selection of the drug-resistant CEM/VP-1 subline has been
described previously (Patel et al., 1990). Briefly, CCRF-CEM
cells were cultured over several weeks in the presence of
sublethal amounts of etoposide (80-160 nM). Resistant cells
were then challenged intermittently and repeatedly (3-4
times) with each incremental concentration (0.32, 0.8, 1.0 and
1.6 fM) of etoposide (Bristol-Myers Co, Syracuse, NY),
allowing for recovery of cultured cells during the procedure.
Cell counts and cell viability were assessed using a
haemocytometer and Trypan Blue dye exclusion, respectively.
Cells resistant to the different levels ofetoposide were subcul-
tured and stocks were frozen in liquid nitrogen. Subse-
quently, cells selected at 0.8tLM (but not 0.32pM) drug could
be grown up from frozen stocks and were designated CEM/
0.8. The CEM/VP-l subline was derived from cells able to
grow in 1.6ILM etoposide and was obtained by cloning in soft
agarose in the absence of drug (Patel et al., 1990). Drug
cytotoxicities were determined by the method of Conter and
Beck, 1984 and were expressed as IC50 values, the drug
concentration that inhibits cell growth by 50% compared to
control cells. The resistant phenotype of CEM/VP-l cells
appeared to be stable: cells could be grown over long periods
in the absence of drug without loss of resistance.
Karyotype analysis
Cytogenetic analysis of parental CEM and drug-resistant
sublines was performed at the same time using the standard
G-banding technique (Trent & Thompson, 1987). Logarith-
mically growing cultures, were prepared for chromosome
analysis by pretreatment for 4 h with colchicine to arrest cells
in mitosis. The cells were collected by gentle centrifugation,
resuspended in a hypotonic 0.075 M potassium chloride solu-
tion, recovered by centrifugation and fixed in methanol:acetic
acid (3:1). Slides were prepared by air drying. The spreads
were trypsinised in 0.1% trypsin for 2 min after which they
were stained with Giemsa. Karyotypes are described accord-
ing to the International System for Cytogenetic Nomencla-
ture, 1978.
PCR/DNA sequence analysis ofTOP2ax cDNAfrom cell lines
Total cellular RNA was isolated from CEM, CEM/0.8 and
CEM/VP-1 cells (1.5 x I07cells) by the guanidinium thio-
cyanate method (Chirgwin et al., 1979) and used for first
strand TOP2ax cDNA synthesis. RNA (2pg) was primed for
cDNA synthesis with one of three 18-mer TOP2a antisense
oligonucleotides: oligo 2, 5' TATGAGAAGCTTCTCGAA
(nucleotide positions 1492-1475); oligo 4, 5' TAGCCTG-
GTACCAAACTG (2379-2362); or oligo 6, 5' CTTAGC-
CTGCAGAGTTCA (3440-3423) (nucleotide numbering
system based on the TOP2ax sequence of Tsai-Pflugfelder et
al., 1988, which labels base 1 as the A of the ATG initiation
codon). First strand cDNA synthesis was carried out using
moloney murine leukaemia virus reverse transcriptase
(Gibco-BRL, Paisley, Scotland) according to the manufac-
turer's instructions (20jil total volume). Polymerase chain
reactions were carried out using these cDNA products
primed with oligos 2, 4 or 6 and the sense oligonucleotides: 1,
5' ATGGAAGTGTCACCATTG (1-18); 3, 5' TTCGAG-
AAGCTTCTCATA (1475-1492); or 5, 5' CAGTTTG-
GTACCAGGCTA (2362-2379) (Figure 2). Each first strand
cDNA product (4pl) was added to PCR reaction mixtures
containing 50 pmol of each oligonucleotide primer, 200 gM
(each) dNTP and 2.5 U Taq polymerase (Cambio, Cam-
bridge, UK) in 100 ll reaction buffer (50 mM KCI/10 mM
Tris-HCl/1.5 mM MgCl2/0.1 mgmhII gelatin, pH 8.0). PCR
conditions were: 95°C, 1 min; 50°C, 1 min; 74°C, 3 min; 30
cycles. PCR products were precipitated with ethanol, digested
with restriction enzymes (Northumbria Biologicals Ltd.,
Northumberland, UK) and the resulting fragments ligated
into appropriately cut M13mpl8 or pBluescript II S/K+
vectors (Stratagene Ltd., Cambridge, UK) prior to transfor-
mation of E. coli XL-1 Blue, as recommended by Amersham
International (Little Chalfont, Bucks, UK). DNA was
sequenced by the dideoxy chain termination method (Sanger
et al., 1977) using Sequenase version 2.0 (US Biochemicals)
and [c-35S]dATP (Amersham). DNA sequencing reactions
were run on 6% denaturing polyacrylamide gels which were
fixed in 10% acetic acid-10% methanol for 30 min, dried and
autoradiographed on Fuji X-ray film. DNA sequences were
analysed using the PC/Gene software package (Intelli-
Genetics, Mountain View, California).
Allele-specific oligonucleotide hybridisation to TOP2a cDNA
PCR products derived from CEM, CEM/0.8 and CEM/VP-I
cDNA using oligo pair 5/6 (Figure 2) were electrophoresed on
a 0.8% agarose gel, blotted on to nylon membranes and
prehybridised for 4 h at 45°C in 5 x SSPE (1 x SSPE is
10 mM sodium phosphate, pH 7.2/0.18 M NaCI/ mM Na3
EDTA, pH 7.4) containing 7% SDS, 5 x Denhardt's reagent
and 100 ,ug ml-' salmon sperm DNA. Hybridisation was
overnight at 45°C in the same buffer containing either 5,32p_
labelled oligo S (5' AGCAGAATCCTTGCCACCAT) or R
(5' AGCAGAATCATTGCCACCAT). Filters were washed
at room temperature for 20 min in 2 x SSPE/0.1% SDS and
then for I h at 55°C in 5 x SSPE/0.1% SDS. Filters were
subjected to a final wash in 5 x SSPE/0.1% SDS for 10 min
at either 60°C (oligo S probe) or 58°C (oligo R probe),
respectively. (These temperatures were the calculated Tm s for
each oligonucleotide). Autoradiography was at room
temperature for 1-2 h using Amersham Hyperfilm.
Immunological detection oftopo IIa and IIP
Nuclear proteins (100jg), prepared from logarithmically-
growing CEM cell lines (Danks et al., 1988), were separated
by electrophoresis on 7.5% sodium dodecyl sulphate-
polyacrylamide gels (samples to be analysed for topo Ila and
P were boiled for 2 min or heated at 68°C for 5 min respec-
tively, prior to loading). Proteins were transferred to nitrocel-
lulose membranes which were blocked overnight in TBST
buffer (10 mM Tris-HCI, pH 7.5, 0.15 M NaCl, 0.05% Tween)
containing 1% BSA (the latter was omitted for filters to be
probed for topo Ilp). Filters were probed by incubation for
2 h at room temperature with an affinity-purified rabbit anti-
topo llcx antiserum (kindly provided by Dr F. Drake, Smith-
Kline Beecham, King of Prussia, USA) diluted 1:1000 in
TBST, Topo II1 was detected by incubating membranes for
2 h at 37°C with an affinity purified anti-topo II3 antiserum
(raised against a synthetic topo IIP peptide sequence by Dr
Caroline Austin of this laboratory) diluted 1:200 in TBST
containing 0.1% SDS. Blots were washed three times in
TBST for 3-5 min each and then incubated for 2 h with goat
anti-rabbit IgG alkaline phosphatase conjugate (Sigma Co,
Poole, UK)) diluted 1:1000. Filters were washed three times
with TBST for 5 min prior to development of colour reac-
tions using nitroblue tetrazolium and BCIP (5-bromo-4-
chloro-3-indoyl phosphate) (Promega) according to the
manufacturer's instructions. Sizes of immunoreactive bands
were determined by running protein markers alongside and
whose position could be located on the nitrocellulose filter by
staining with Amido black.458 S. PATEL & L.M. FISHER
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Figure I Cytogenetic analysis of CEM a, and CEM/VP-1I b, cells by the G banding method. a, Karyotype of the drug-sensitive CEM cell line: arrows denote structural alterations del(8) (pllI-pter), del(9) (p1I3-pter), t(9,?) (p22,?) and +20. b, CEM/VP-I cells were diploid and exhibited the same chromosome abnormalities with an additional del(3) (pl3-pter) alteration.ETOPOSIDE RESISTANCE IN HUMAN LEUKAEMIC CELLS 459
Other methods
Oligonucleotides were made on a Cyclone Plus DNA syn-
thesiser (Milligen/Biosearch, Ltd) using phosphoramidite
chemistry. Protein concentrations were determined by the
method of Bradford, 1976 using bovine plasma albumin as a
standard.
Results
Preferential selection ofCEMIVP-Ifrom a diploid
subpopulation: an acquired chromosome 3p deletion affects one
TOP2P allele
Chromosome banding analysis was carried out on 20 meta-
phase spreads from both CEM and CEM/VP-1 cell lines
(Figure 1). CEM cells were largely tetraploid (n = 94) and
carried extra copies of chromosome 20 (Figure la). Survey of
a large number of spreads revealed that approximately 1% of
CEM cells were diploid (n = 47) with chromosome 20 in
extra copy. Three structural abnormalities were identified for
the diploid and tetraploid CEM cells: del(8) (p1 l-pter), del(9)
(pl3-pter) and t(9;?) (p22;?). Surprisingly, the CEM/VP-1 cell
line was found to be diploid (n = 47, + 20), exhibiting the
same numerical and structural abnormalities as CEM cells
(Figure lb). However, one homologue of chromosome 3 in
the CEM/VP-1 cell line had acquired the additional abnor-
mality, del(3) (p13-pter). This 3p region was not visible
elsewhere in the chromosome spread consistent with its dele-
tion or a complex rearrangement. No marker chromosomes,
double minutes or homogenously staining regions were
observed in any of the metaphase spreads examined for
either parental or resistant cells. The results establish that the
etoposide-resistant cell line has two copies of chromosome 17
on which maps the TOP2 allele (17p2l-22) coding for p170
topoisomerase II (Tsai-Pflugfelder et al., 1988), and most
likely only one allele for the p180 isoform, provisionally
mapped at 3p24-25 (Tan et al., 1992).
The resistant cell line appeared to have been selected from
the 1% diploid subgroup of CEM cells (from which the
tetraploid population presumably also originated during
extended culture of the CEM line). This view is supported by
karyotype analysis of CEM/0.8 cells which were inter-
mediates in the stepwise selection of CEM/VP-1 and were
-10-fold more resistant to etoposide than parental cells
(data not shown). Diploid cells (n = 47) accounted for 87 of
the 100 CEM/0.8 metaphases examined, with the remainder
being tetraploid (data not shown). Each type of spread
showed the same structural abnormalities as observed in the
respective diploid and tetraploid CEM cells. However, both
number 3 chromosomes appeared normal in the diploid
1
BamHI Hind III
I I
CEM/0.8 cells suggesting that the del(3) (pl3-pter) change
observed in CEM/VP-1 cells occurred later in the selection
process.
A novel TOP2a mutation is acquired during etoposide selection
Previously, we showed that topo II activity in CEM/VP-1
nuclear extracts was not inhibited by etoposide and did not
mediate drug-induced DNA cleavage in vitro (Patel et al.,
1990). These properties are reminiscent of 4-quinolone resist-
ance in Escherichia coli strains arising from mutation of
DNA gyrase, a bacterial DNA topoisomerase II. Mutations
in gyrase A protein adjacent to the catalytic Tyr-122 residue
engaged in DNA breakage-reunion generate a drug resistant
supercoiling activity and abolish quinolone induced DNA
breakage by the complex (Cullen et al., 1989; Yoshida et al.,
1990). The analogy with the gyrase system led us to search
for potential etoposide resistance mutations in the p170
TOP2 cDNA of the CEM/VP-1 cell line, focusing on the
region surrounding codon-804 which specifies the tyrosine
residue implicated in transient DNA breakage-reunion (Tsai-
Pflugfelder et al., 1988; Wyckoff et al., 1989).
PCR products A-C, spanning the p170 TOP2 cDNA
sequence from CEM and CEM/VP-1 cells, were obtained by
first strand cDNA/PCR amplification from total cellular
RNA using three sets of oligonucleotide primers, 1/2, 3/4 and
5/6 (Figure 2). These 1.5, 0.88 and 1.0 kb products were
digested with BamHI/HindIII, HindIII/KpnI and KpnI/
BamHI, respectively and cloned into Ml3mpl8 or Bluescript
allowing DNA sequence analysis. DNA sequence obtained
from the KpnI ends of fragments B and C covered codons
740-840 including the catalytic Tyr-804 codon. Four
independent clones of fragment C derived from the CEM/
VP-1 cell line and nine clones from sensitive CEM cells were
analysed and compared to the HeLa p170 cDNA sequence
(Tsai-Pflugfelder et al., 1988). Three of the four CEM/VP-1
clones carried a single base change, a G+T transversion at
nucleotide position 2391 (Figure 3a), corresponding to a
Lys-797-*Asn substitution at the protein level. The fourth
clone was identical in sequence to HeLa p170 cDNA in this
region (data not shown). None of the nine CEM-drived
clones differed in sequence from that of the HeLa p170
cDNA (Figure 3a). Thus, the diploid CEM/VP-1 cells appear
to express two TOP2a alleles encoding wild-type and mutant
797 protein residues.
Allele-specific hybridisation
Expression of TOP2a alleles in the resistant CEM/VP-1 cells
was further analysed by oligonucleotide hybridisation
(Figures 3b and 4). Allele-specific antisense oligonucleotides
Kpn
k7
BamHI
4591
.- *- *
A
1 | 12
B
3 - 4
51 16
1 Kb
Figure 2 Restriction map of the full length human p170 TOP2 cDNA (heavy line) showing regions a-c, amplified by polymerase
chain reaction from a first strand cDNA derived from CEM and CEM/VP-1 cell RNA. Restriction sites for BamHI, HindIII and
KpnI are indicated. The A of the ATG initiation codon and the T of the TAA stop codon are labelled as nucleotide positions 1 and
4591, respectively, as in Tsai-Pflugfelder et al., 1988. Antisense oligos 2, 4 and 6 were used for first strand cDNA synthesis; oligos
1/2, 3/4 and 5/6 were used in PCR reactions to obtain products A-C (see text for details). Open triangle shows the position of
codon 804 which specifies the catalytic Tyr residue involved in transient DNA breakage-reunion. Filled circles locate codons 449,
486; asterisk, codon 797. Lines below cDNA indicate DNA sequence determined for PCR products. Bar denotes I kilobase pairs.460 S. PATEL & L.M. FISHER
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Figure 3 Identification of a Lys-797->Asn codon change in the p170 TOP2 cDNA from etoposide-resistant CEM/VP-I cells. PCR
product C was digested with KpnI and BamHI (Figure 2), subcloned into pBluescript II S/K+ and sequenced directly by the
dideoxy chain termination method (Sanger et al., 1977). a, Sequencing gel showing a region of coding strand DNA encompassing
codon 797. Asterisk indicates a G-T change at nucleotide position 2391 in the resistant CEM/VP-1 cDNA that is absent in the
TOP2cc coding sequence of parental CEM cells. b, CEM/VP-1 mutation in p170 topo II lies close to the catalytic tyrosine residue
804. Diagram also shows the sequence of two antisense oligonucleotides S and R designed to detect normal and mutant alleles,
respectively. The base change in the mutant oligo R is underlined.
were synthesised corresponding to normal (oligo S) or
mutant CEM/VP-1 (oligo R) sequences encompassing codon
797 (Figure 3b). Equal amounts (approximately 0.4 lg) of
PCR product C made from CEM and CEM/VP-1 cDNA
were electrophoresed in a 0.8% agarose gel, blotted on to
nylon filters and probed with 5' end-labelled oligo S or oligo
R. PCR product from CEM/VP-1 cells hybridised to both
mutant and normal oligonucleotide probes whereas that from
a
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CEM
CEMNP-1
b
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0
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0
CEM
CEMNP-1
Figure 4 Mutant (Lys-797-Asn) p170 TOP2 allele is expressed
in the etoposide-resistant CEM/VP-1 cell line, but not in sensitive
CEM cells. Allele specific oligonucleotide hybridisation to PCR
product C derived from cDNA of drug sensitive and etoposide-
resistant CEM/VP-1 cells. PCR products were run on a 0.8%
agarose gel, transferred to nylon filters and hybridised to 5'
32P-labelled oligo S (a) or oligo R (b) (see Figure 3 legend).
CEM cells hybridised only with oligo S (Figure 4). These
results confirm the expression of one mutant TOP2a allele in
etoposide-resistant cells and its absence in drug sensitive
parental CEM cells.
By using the same approach, it was found that the codon
797 TOPa mutation was present in CEM/0.8 cells, inter-
mediates in the isolation of CEM/VP-1 (data not shown).
Thus, mutation of Lys-797 in topo Ila appears to be an early
event in selection for etoposide resistance.
Absence ofcodon 449 and 486 TOP2a mutations
DNA sequence was determined for four CEM/VP-1 clones of
PCR product A corresponding to TOP2a codons 381-495.
This region contains codons 449 and 486 which are known to
be altered in m-AMSA resistant HL60 and teniposide resist-
ant CEM cell lines (Bugg et al., 1991; Hinds et al., 1991; Lee
et al., 1992). However, each CEM/VP-1 cDNA sequence was
identical to that reported for HeLa TOP2a cDNA (Tsai-
Pflugfelder et al., 1988): there was no evidence of coding
changes in this region (data not shown).
Topo Ia and11p protein levels
Western blot analysis revealed that CEM cells express both a
and ,B isoforms of topo II and that roughly similar levels (to
within 2-fold) were present in CEM/VP-1 cells (Figure 5).
These results parallel our previous work showing that resist-
ant cells had no more than a 2-fold reduction in topo-
isomerase II activity (Patel et al., 1990). Thus, although the
effects of ploidy and of the relative contributions of cc and P
isoforms to topo II activity are not known, etoposide resist-
ance in the CEM/VP-1 cell line did not appear to involve the
elimination or marked down-regulation of either topo II
isoform.ETOPOSIDE RESISTANCE IN HUMAN LEUKAEMIC CELLS 461
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Figure 5 Western blot analysis of topo Ila and topo I1p levels in nuclear extracts of CEM and CEM/VP-l cell lines. DNA
topoisomerase II was extracted with 1 M NaCI from nuclei of logarithmically growing cells. Equal amounts of nuclear proteins were
separated on a 7.5% SDS-PAGE gel, transferred to nitrocellulose and probed with anti-topo IIa and anti-topo IIP antisera. Two
immunoreactive bands migrating at -90 kDa are possible proteolysis products of the P isoform.
Discussion
Etoposide has become a clinically important anticancer agent
(Liu, 1989). The drug exerts its cytotoxic effects by interfer-
ing with DNA breakage-reunion by topoisomerase II trap-
ping a cleavable complex of the enzyme on DNA (Ross et
al., 1984; Liu, 1989). However, its exact mechanism of action
and the pathways of cellular resistance are poorly under-
stood. The aim of this study was to characterise the genetic
alterations associated with selection for etoposide resistance
in human leukaemic CCRF-CEM cells. We have obtained
evidence for multiple and novel genetic changes affecting
both TOP2c and TOP2P genes in the resistant cell line,
CEM/VP-1. Perhaps the most striking and unexpected
feature of the cell line was its diploid karyotype which con-
trasts with the tetraploid karyotype of the sensitive parental
cells (Figure 1). Chromosome analysis revealed that the
CEM/VP-1 line was preferentially selected from a diploid
CEM subpopulation constituting about 1% of the starting
cells (Figure 1). To our knowledge, this is the first report of
preferential selection for resistant diploid cells by an inhibitor
of topoisomerase II.
Diploid selection and multiple events in the development
of resistance may be rationalised if at-MDR in CEM cells
selected with etoposide has a recessive phenotype, as shown
for CEM cell lines resistant to teniposide, a closely related
topo II inhibitor (Wolverton et al., 1989). In bacteria, quino-
lone resistant gyrA genes are recessive to the wild type gyrA
allele reflecting the fact that quinolone drugs act by trapping
sensitive enzyme on DNA (discussed in Cullen et al., 1989).
Similarly the recessivity of at-MDR appears to involve TOP2
genes as evidenced by the drug resistant topo II activity of
CEM cells selected with etoposide or teniposide (Danks et
al., 1988; Patel et al., 1990). Depending on the relative con-
tributions of a and P isoforms to topo II activity, mutations
at each TOP2a and/or TOP2P allele might then be required
for development of resistance. Clearly, the fewer TOP2 alleles
that must be mutated, the easier it will be for resistance to
develop, favouring diploid over tetraploid cells. Another con-
tributory factor could be that conceivably the parental dip-
loid cells are intrinsically less sensitive to etoposide than their
tetraploid derivatives. At present, the effects of ploidy on
topo II levels and on etoposide sensitivity are unknown and
warrant further examination. Whatever its molecular basis,
selection of diploid cells has practical importance. Unlike the
complex karyotypes of many resistant cell lines (Bugg et al.,
1991; Hinds et al., 1991; Lee et al., 1992), the diploid comple-
ment of CEM/VP-1 (lacking marker or double minute
chromosomes, Figure 1) greatly facilitates genetic analysis of
its TOP2 genes.
One of the two TOP2c alleles expressed in CEM/VP-1 cells
encodes a novel Lys-797-*Asn mutation. Lys-797 is a con-
served residue in topo IIa that lies adjacent to Tyr-804
implicated in enzymatic DNA breakage-reunion (Wyckoff et
al., 1989). Mutation of Lys-797 in topo IIa could confer
resistance by impairing cleavable complex formation consis-
tent with the inability of topo II activity from CEM/VP-1
cells to promote etoposide-dependent DNA breakage (Patel
et al., 1990). Precedent for this idea comes from identification
of nalidixic acid mutations which lie in a conserved region
(residues 67-106) of gyrase A protein adjacent to catalytic
Tyr-122 in the DNA breakage-reunion domain of the enzyme
and which circumvent drug-mediated DNA cleavage by
gyrase (Cullen et al., 1989; Yoshida et al., 1990). These
features suggest that mutation of Lys-797 may play a direct
role in etoposide resistance by producing a drug resistant
enzyme activity. Interestingly, the Lys-797 - Asn TOP2a
codon change was present in the CEM/0.8 cells indicating it
was an early event in the selection process.
Recent work has identified two other TOP2ca mutations in
resistant cell lines. Partial TOP2a cDNA sequence analysis
showed that two teniposide resistant CEM resistant cell lines
with a pseudotriploid karyotype encode topo IIa proteins
with wild type Arg-449 and mutant Gln-449 residues (Bugg
et al., 1991). An Arg-486-* Lys alteration in topo IIa has
been described in amsacrine-resistant HL60 and KBM-3 cell462 S. PATEL & L.M. FISHER
lines (Hinds et al., 1991; Lee et al., 1992). In contrast to
Lys-797, these residues lie in the putative ATP binding
domain of the topo Ila protein and are comparable in loca-
tion to residues conferring resistance to nalidixic acid in E.
coli DNA gyrase B protein (Yoshida et al., 1991). Studies of
T4 phage topoisomerase II have revealed that mutations in
either DNA breakage-reunion- or ATPase-subunits render
the enzyme resistant to amsacrine (Huff et al., 1990). Neither
the 449 or 486 change was found in CEM/VP-l cells. The
variety of mutations thus far associated with resistance to
topo II inhibitors may arise from differences among the
selecting drugs, cell types or final levels of drug resistance.
The drug resistant topo II activity in CEM/VP-1 cells
presumably involves one or more TOP2 resistance mutations,
of which the Lys-797-*Asn change may be considered a
candidate. However, given the recessive phenotype of at-
MDR, it is also conceivable that mutations causing down-
regulation of TOP2 gene expression, loss of TOP2 alleles or
functional inactivation of topo II proteins could contribute
to the development of resistance. Loss-of-function mutations,
widely encountered in the context of tumour suppressor
genes (Weinberg, 1991), could in principle serve to reduce
levels of drug sensitive topo II by inactivating one or more
TOP2 alleles. The 3p- deletion of one TOP2P3 allele seen in
CEM/VP-1 cells (Figure 1) may belong to this category. It is
not known whether point mutations in topo IIa at positions
449, 486 or 797 identified in resistant cell lines have altered
function or loss of function phenotypes. This distinction
must await the development of appropriate TOP2 gene ex-
pression systems allowing purification and analysis of mutant
topo II proteins.
Resistance to etoposide is a common problem in cancer
chemotherapy. The initial drug sensitivity of some tumours
appears to correlate with topo II activity and content. Thus,
the favourable response of SCLC to etoposide compared to
the relative insensitivity of non-small lung cell carcinoma
parallels increased topo II levels seen in SCLC- as compared
with NSCLC-cell lines (Kasahara et al., 1992). However, the
factors responsible for the subsequent development of resis-
tance in SCLC and leukaemia are largely unknown. The
possibility that mutations in TOP2 genes are involved has
received little attention. Clearly, it will be important to
examine whether codon-797 and other TOP2ac (and TOP2P)
mutations identified in cell lines also play a role in clinical
resistance.
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